Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells

被引:13
|
作者
Grespi, Francesca [1 ]
Landre, Vivien [2 ]
Molchadsky, Alina [3 ]
Di Daniele, Nicola [4 ]
Marsella, Luigi Tonino [4 ]
Melino, Gerry [2 ,4 ]
Rotter, Varda [3 ]
机构
[1] Univ Padua, Dept Biol, Padua, Italy
[2] Univ Leicester, Med Res Council, Toxicol Unit, Lancaster Rd,POB 138,Hodgkin Bldg, Leicester LE1 9HN, Leics, England
[3] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
[4] Univ Roma Tor Vergata, Fac Med & Surg, Rome, Italy
来源
CELL DEATH & DISEASE | 2016年 / 7卷
基金
英国医学研究理事会;
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; DNA-DAMAGE RESPONSE; GAIN-OF-FUNCTION; OSTEOBLAST DIFFERENTIATION; MUSCLE DIFFERENTIATION; LUNG TUMORIGENESIS; PROSTATE-CANCER; DOWN-REGULATION; BREAST-CANCER; TUMOR-GROWTH;
D O I
10.1038/cddis.2016.419
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The tumour suppressor p53 plays an important role in somatic cell reprogramming. While wild-type p53 reduces reprogramming efficiency, mutant p53 exerts a gain of function activity that leads to increased reprogramming efficiency. Furthermore, induced pluripotent stem cells expressing mutant p53 lose their pluripotency in vivo and form malignant tumours when injected in mice. It is therefore of great interest to identify targets of p53 (wild type and mutant) that are responsible for this phenotype during reprogramming, as these could be exploited for therapeutic use, that is, formation of induced pluripotent stem cells with high reprogramming efficiency, but no oncogenic potential. Here we studied the transcriptional changes of microRNA in a series of mouse embryonic fibroblasts that have undergone transition to induced pluripotent stem cells with wild type, knock out or mutant p53 status in order to identify microRNAs whose expression during reprogramming is dependent on p53. We identified a number of microRNAs, with known functions in differentiation and carcinogenesis, the expression of which was dependent on the p53 status of the cells. Furthermore, we detected several uncharacterised microRNAs that were regulated differentially in the different p53 backgrounds, suggesting a novel role of these microRNAs in reprogramming and pluripotency.
引用
收藏
页码:e2567 / e2567
页数:8
相关论文
共 50 条
  • [21] Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts
    Watanabe, T
    Sullenger, BA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) : 8490 - 8494
  • [22] Elevated p53 Activities Restrict Differentiation Potential of MicroRNA-Deficient Pluripotent Stem Cells
    Liu, Zhong
    Zhang, Cheng
    Skamagki, Maria
    Khodadadi-Jamayran, Alireza
    Zhang, Wei
    Kong, Dexin
    Chang, Chia-Wei
    Feng, Jingyang
    Han, Xiaosi
    Townes, Tim M.
    Li, Hu
    Kim, Kitai
    Zhao, Rui
    STEM CELL REPORTS, 2017, 9 (05): : 1604 - 1617
  • [23] Study on The Mechanism of Reactivation of Mutant p53 to Wild-type-like p53 by Andrographolide
    Song Bin
    Wang Jia-Jian
    Su Yong-Nan
    Wang Yu-Ling
    Yang Fan
    Zhang Ji-Hong
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2022, 49 (09) : 1763 - 1773
  • [24] Mutant p53: Gain-of-function oncoproteins and wild-type p53 inactivators
    Roemer, K
    BIOLOGICAL CHEMISTRY, 1999, 380 (7-8) : 879 - 887
  • [25] Aspirin acetylates wild type and mutant p53 in colon cancer cells: Identification of aspirin acetylated sites on recombinant p53
    Ai, Guoqiang
    Dachineni, Rakesh
    Kumar, Ramesh D.
    Marimuthu, Srinivasan
    Alfonso, Lloyd F.
    Bhat, Jayarama G.
    CANCER RESEARCH, 2016, 76
  • [26] Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53
    Ai, Guoqiang
    Dachineni, Rakesh
    Kumar, D. Ramesh
    Marimuthu, Srinivasan
    Alfonso, Lloyd F.
    Bhat, G. Jayarama
    TUMOR BIOLOGY, 2016, 37 (05) : 6007 - 6016
  • [27] WILD-TYPE P53 SUPPRESSES GROWTH OF HUMAN PROSTATE-CANCER CELLS CONTAINING MUTANT P53 ALLELES
    ISAACS, WB
    CARTER, BS
    EWING, CM
    CANCER RESEARCH, 1991, 51 (17) : 4716 - 4720
  • [28] Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53
    Gjerset, RA
    Turla, ST
    Sobol, RE
    Scalise, JJ
    Mercola, D
    Collins, H
    Hopkins, PJ
    MOLECULAR CARCINOGENESIS, 1995, 14 (04) : 275 - 285
  • [29] WILD-TYPE P53 SUPPRESSES THE MALIGNANT PHENOTYPE IN BREAST-CANCER CELLS CONTAINING MUTANT P53 ALLELES
    RUNNEBAUM, IB
    YEE, JK
    KIEBACK, DG
    SUKUMAR, S
    FRIEDMANN, T
    ANTICANCER RESEARCH, 1994, 14 (3A) : 1137 - 1144
  • [30] Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
    Phong Lu
    Erica R. Vander Mause
    Katherine E. Redd Bowman
    Sarah M. Brown
    Lisa Ahne
    Carol S. Lim
    Journal of Ovarian Research, 12